239 related articles for article (PubMed ID: 30037803)
21. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
[TBL] [Abstract][Full Text] [Related]
22. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.
Stahl M; Bewersdorf JP; Giri S; Wang R; Zeidan AM
Haematologica; 2020 Jan; 105(1):102-111. PubMed ID: 31004015
[TBL] [Abstract][Full Text] [Related]
23. [Immunosuppressive therapy using antithymocyte globulin and cyclosporin A with or without human granulocyte colony-stimulating factor in children with acquired severe aplastic anemia].
Liu X; Zou Y; Wang S; Zhang L; Yang W; Zhang J; Liu F; Liu T; Chen X; Ruan M; Zhou J; Cai X; Qi B; Chang L; An W; Guo Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):84-9. PubMed ID: 24739716
[TBL] [Abstract][Full Text] [Related]
24. Relationship between plasma rabbit anti-thymocyte globulin concentration and immunosuppressive therapy response in patients with severe aplastic anemia.
Narita A; Muramatsu H; Ichikawa D; Hamada M; Nishikawa E; Suzuki K; Kawashima N; Okuno Y; Nishio N; Hama A; Yamazaki H; Nakao S; Kojima S; Takahashi Y
Eur J Haematol; 2021 Aug; 107(2):255-264. PubMed ID: 33949001
[TBL] [Abstract][Full Text] [Related]
25. Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Santini V; Giagounidis A; Pelligra CG; Franco-Villalobos C; Tang D; Morison J; Beach CL; Hu A; Platzbecker U; Fenaux P
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e874-e883. PubMed ID: 35710702
[TBL] [Abstract][Full Text] [Related]
26. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
27. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.
Führer M; Burdach S; Ebell W; Gadner H; Haas R; Harbott J; Janka-Schaub G; Klingebiel T; Kremens B; Niemeyer C; Rampf U; Reiter A; Ritter J; Schulz A; Walther U; Zeidler C; Bender-Götze C
Klin Padiatr; 1998; 210(4):173-9. PubMed ID: 9743949
[TBL] [Abstract][Full Text] [Related]
28. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
Komrokji RS; Al Ali NH; Sallman D; Padron E; DeZern AE; Barnard J; Roboz GJ; Garcia-Manero G; List A; Steensma DP; Sekeres MA
Cancer Med; 2021 Jan; 10(2):447-453. PubMed ID: 33350168
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
Boddu P; Garcia-Manero G; Ravandi F; Borthakur G; Jabbour E; DiNardo C; Jain N; Daver N; Pemmaraju N; Anderlini P; Parmar S; Kc D; Akosile M; Pierce SA; Champlin R; Cortes J; Kantarjian H; Kadia T
Am J Hematol; 2017 Dec; 92(12):1295-1302. PubMed ID: 28850699
[TBL] [Abstract][Full Text] [Related]
30. Aplastic anemia in children: How good is immunosuppressive therapy?
Jain R; Trehan A; Bansal D; Varma N
Pediatr Hematol Oncol; 2019 May; 36(4):211-221. PubMed ID: 31287349
[TBL] [Abstract][Full Text] [Related]
31. Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia.
Wang H; Liu H; Wang T; Li L; Liu C; Li L; Chen T; Qi W; Ding K; Fu R
J Clin Lab Anal; 2021 Mar; 35(3):e23667. PubMed ID: 33249661
[TBL] [Abstract][Full Text] [Related]
32. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
[TBL] [Abstract][Full Text] [Related]
33. Response To Immunosuppressive Therapy In Patients Of Acquired Aplastic Anaemia: A Single Center Experience From A Developing Country.
Khan M; Iftikhar R; Chaudhry QU; Mehmood SK; Faraz T; Ghafoor T; Shahbaz N; Khan MA; Shamshad GU; Khattak TA
J Ayub Med Coll Abbottabad; 2022; 34(Suppl 1)(4):S969-S973. PubMed ID: 36550655
[TBL] [Abstract][Full Text] [Related]
34. Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study.
Zhu XF; He HL; Wang SQ; Tang JY; Han B; Zhang DH; Wu LQ; Wu DP; Li W; Xia LH; Zhu HL; Liu F; Shi HX; Zhang X; Zhou F; Hu JD; Fang JP; Chen XQ; Ye TZ; Liang YM; Jin J; Zhang FK
Acta Haematol; 2019; 142(3):162-170. PubMed ID: 31091521
[TBL] [Abstract][Full Text] [Related]
35. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of transfusion-dependent nonsevere aplastic anemia with cyclosporine A plus ATG/ALG versus cyclosporine A plus androgens: a retrospective single center study].
Song L; Peng GX; Wu ZJ; Zhang L; Jing LP; Zhou K; Li Y; Li Y; Ye L; Li JP; Fan HH; Zhao X; Yang WR; Yang Y; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):946-951. PubMed ID: 27995878
[TBL] [Abstract][Full Text] [Related]
37. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
38. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Wattel E; Solary E; Leleu X; Dreyfus F; Brion A; Jouet JP; Hoang-Ngoc L; Maloisel F; Guerci A; Rochant H; Gratecos N; Casassus P; Janvier M; Brice P; Lepelley P; Fenaux P
Leukemia; 1999 Apr; 13(4):524-9. PubMed ID: 10214857
[TBL] [Abstract][Full Text] [Related]
39. Modified immunosuppressive therapy with porcine antilymphocyte globulin plus delayed cyclosporine A in children with severe aplastic anemia.
Cui Q; Sha P; Chen H; Shen H; Qin L; Li Z; Wu T; Wang Z
Int J Hematol; 2018 Jan; 107(1):64-68. PubMed ID: 28900860
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
